# Imatinib in Acute Ischaemic Stroke

> **NCT03639922** · PHASE3 · UNKNOWN · sponsor: **Niaz Ahmed** · enrollment: 1260 (estimated)

## Conditions studied

- Acute Ischaemic Stroke

## Interventions

- **DRUG:** Imatinib 400mg
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03639922
- **Lead sponsor:** Niaz Ahmed
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2022-12
- **Final completion:** 2023-06
- **Target enrollment:** 1260 (ESTIMATED)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639922, "Imatinib in Acute Ischaemic Stroke". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03639922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*